Ionis Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from BMO Capital upgraded the rating on the stock to a Buy and gave it a $70.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kostas Biliouris has given his Buy rating due to a combination of factors that suggest strong future performance for Ionis Pharmaceuticals. One of the key reasons is the promising data from Olezarsen, which has shown better-than-expected benefits in addressing acute pancreatitis, positioning it as a potential blockbuster drug in the U.S. market. Additionally, the anticipated positive outcomes from significant readouts in 2026 for the Lp(a) and ATTR-CM programs are expected to drive further momentum for the company.
Beyond these developments, Ionis Pharmaceuticals is poised for potential profitability around 2027, which is an attractive prospect in the current uncertain market environment. The company’s Angelman program also presents a multi-billion dollar opportunity, given the lack of approved treatments for this neuro-genetic disorder. Overall, Biliouris believes that while Ionis could benefit from a more focused pipeline, the risk/reward profile is skewed positively, making it a compelling investment opportunity.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $69.00 price target.